Prospective Grant of Exclusive License: Methods for Using Extracellular Adenosine Inhibitors and Adenosine Receptor Inhibitors as Applied to the Treatment of Human Cancer and Tumors, 18419 [05-7248]

Download as PDF Federal Register / Vol. 70, No. 68 / Monday, April 11, 2005 / Notices limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.892, 93.893, National Institutes of Health HHS) Dated: April 4, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy [FR Doc. 05–7245 Filed 4–8–05; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Methods for Using Extracellular Adenosine Inhibitors and Adenosine Receptor Inhibitors as Applied to the Treatment of Human Cancer and Tumors National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in Patent Applications U.S. 60/340,772, filed on 12/12/2001, U.S. 60/342,582, filed on 12/19/2001, PCT/ US2002/036829, filed on 11/14/2002, and corresponding EP, CA, AU, and JP filings, as well as U.S. 10/498,416, filed on 06/10/2004; entitled ‘‘Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation’’, all by Michail V. Sitkovsky and Akio Ohta, to Adenosine Therapeutics, LLC, having a place of business in Charlottesville, VA. The patent rights in this invention have been assigned to the United States of America. DATES: Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before June 10, 2005 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Cristina Thalhammer-Reyero, Ph.D., M.B.A., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, VerDate jul<14>2003 17:45 Apr 08, 2005 Jkt 205001 Rockville, MD 20852–3804; E-mail: ThalhamC@mail.nih.gov; Telephone: 301–435–4507; Facsimile: 301–402– 0220. The technology described and claimed in the subject invention relates to methods to enhance and prolong the body’s immune response as well as to promote targeted tissue damage, such as for tumor destruction, by inhibiting signaling through the adenosine receptor. The inventors have shown that adenosine A2a and A3a receptors play a critical and non-redundant role in down-regulation of inflammation in vivo by acting as the physiological termination mechanism that can limit the immune response. The methods described involve administering either an adenosine-degrading drug or an adenosine receptor antagonist to exert a more effective and durable immune response and inflammation, and more specifically to the subject exclusive license application, to reduce the size of tumors. Furthermore, using the claimed method in combination with conventional anti tumor agent can be an effective treatment against cancer. The invention has potential applications in the many markets in which therapeutic and preventive uses of manipulating the adenosine pathway are involved, including the regulation of hypoxia, tissue damage, tumor destruction, inflammation, increasing the efficacy of vaccines, and other immune responses. This invention is further described in Ohta A et al., ‘‘Role of G-proteincoupled adenosine receptors in downregulation of inflammation and protection from tissue damage,’’ Nature 2001 Dec 20–27; 414(6866):916–20. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The field of use may be limited to ‘‘Treatment of human cancer and tumors’’. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released SUPPLEMENTARY INFORMATION: PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 18419 under the Freedom of Information Act, 5 U.S.C. 552. Dated: April 4, 2005. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 05–7248 Filed 4–8–05; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF INTERIOR Office of the Secretary Blackstone River Valley National Heritage Corridor Commission: Notice of Meeting Notice is hereby given in accordance with section 552b of title 5, United States Code, that a meeting of the John H. Chafee Blackstone River Valley National Heritage Corridor Commission will be held on Thursday, May 19, 2005. The Commission was established pursuant to Public Law 99–647. The purpose of the Commission is to assist Federal, State and local authorities in the development and implementation of an integrated resource management plan for those lands and waters within the Corridor. The meeting will convene on May 19, 2005, at 7 p.m. at the Burrillville Town Hall at 105 Harrisville Main Street, Harrisville, RI 02830 for the following reasons: 1. Approval of Minutes. 2. Chairman’s Report. 3. Executive Director’s Report. 4. Financial Budget. 5. Public Input. It is anticipated that about twenty-five people will be able to attend the session in addition to the Commission members. Interested persons may make oral or written presentations to the Commission or file written statements. Such requests should be made prior to the meeting to: Larry Gall, Interim Executive Director, John H. Chafee, Blackstone River Valley National Heritage Corridor Commission, One Depot Square, Woonsocket, RI 02895. Tel.: (401) 762–0250. Further information concerning this meeting may be obtained from Larry Gall, Executive Director of the Commission at the aforementioned address. Sue E. Andrews, Chief of Interpretation, BRVNHCC. [FR Doc. 05–7145 Filed 4–8–05; 8:45 am] BILLING CODE 4310–RK–P E:\FR\FM\11APN1.SGM 11APN1

Agencies

[Federal Register Volume 70, Number 68 (Monday, April 11, 2005)]
[Notices]
[Page 18419]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-7248]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Methods for Using 
Extracellular Adenosine Inhibitors and Adenosine Receptor Inhibitors as 
Applied to the Treatment of Human Cancer and Tumors

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license to practice the invention embodied in Patent 
Applications U.S. 60/340,772, filed on 12/12/2001, U.S. 60/342,582, 
filed on 12/19/2001, PCT/US2002/036829, filed on 11/14/2002, and 
corresponding EP, CA, AU, and JP filings, as well as U.S. 10/498,416, 
filed on 06/10/2004; entitled ``Methods for using extracellular 
adenosine inhibitors and adenosine receptor inhibitors to enhance 
immune response and inflammation'', all by Michail V. Sitkovsky and 
Akio Ohta, to Adenosine Therapeutics, LLC, having a place of business 
in Charlottesville, VA. The patent rights in this invention have been 
assigned to the United States of America.

DATES: Only written comments and/or application for a license that are 
received by the NIH Office of Technology Transfer on or before June 10, 
2005 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Cristina Thalhammer-Reyero, Ph.D., M.B.A., 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; E-mail: 
ThalhamC@mail.nih.gov; Telephone: 301-435-4507; Facsimile: 301-402-
0220.

SUPPLEMENTARY INFORMATION: The technology described and claimed in the 
subject invention relates to methods to enhance and prolong the body's 
immune response as well as to promote targeted tissue damage, such as 
for tumor destruction, by inhibiting signaling through the adenosine 
receptor. The inventors have shown that adenosine A2a and A3a receptors 
play a critical and non-redundant role in down-regulation of 
inflammation in vivo by acting as the physiological termination 
mechanism that can limit the immune response. The methods described 
involve administering either an adenosine-degrading drug or an 
adenosine receptor antagonist to exert a more effective and durable 
immune response and inflammation, and more specifically to the subject 
exclusive license application, to reduce the size of tumors. 
Furthermore, using the claimed method in combination with conventional 
anti tumor agent can be an effective treatment against cancer.
    The invention has potential applications in the many markets in 
which therapeutic and preventive uses of manipulating the adenosine 
pathway are involved, including the regulation of hypoxia, tissue 
damage, tumor destruction, inflammation, increasing the efficacy of 
vaccines, and other immune responses.
    This invention is further described in Ohta A et al., ``Role of G-
protein-coupled adenosine receptors in downregulation of inflammation 
and protection from tissue damage,'' Nature 2001 Dec 20-27; 
414(6866):916-20.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use may be limited to ``Treatment of human cancer and 
tumors''.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: April 4, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-7248 Filed 4-8-05; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.